ProKidney Files $650M Shelf and $200M Jefferies ATM Weeks After Going-Concern Warning
PROK is trading near its 52-week low of $1.3 (12% above the low).
Summary
ProKidney filed a $650 million shelf registration that includes a $200 million at-the-market stock program with Jefferies. No shares have been sold yet, but the company has said it may not survive 12 months without new funding.
Key Events · Financing and Capital Events · PROK
-
Shelf and ATM Registered
A Form S-3 registers up to $650,000,000 of Class A common stock, preferred stock, debt securities, warrants, rights and units, including a $200,000,000 at-the-market program with Jefferies LLC.
-
No Shares Sold Yet
The filing registers capacity only; any actual sales require prospectus supplements. Jefferies earns up to 3.0% of gross proceeds and is reimbursed up to $75,000 of counsel fees.
-
Dilution Math at Current Price
Selling the full $200,000,000 at the $1.52 last reported sale price on October 28, 2026 would mean 131,578,947 new shares, taking Class A shares outstanding from 205,716,189 to 337,295,136.
-
Cash Need Is Urgent
The Q2 2026 10-Q previously disclosed substantial doubt about the company's ability to continue as a going concern without new funding; proceeds are earmarked for clinical trials, manufacturing and working capital.
Analysis · PROK · Life Sciences
ProKidney has registered up to $650 million of securities, including a $200 million at-the-market program through Jefferies at a commission of up to 3.0%. No shares have been sold yet — this is capacity, not a completed raise. Context matters here: the Q2 2026 10-Q warned the company may not survive the next 12 months without new funding, and a director sold roughly $1.07 million of stock in August. An ATM is the fastest way to raise cash into strength, but it also means shares can be drip-fed into the market at prices near $1.52, well below the $3.18 weighted-average strike on 39.8 million outstanding options. Actual dilution only happens when 424B supplements are filed and shares are sold.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PROK was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $444.4M. The 52-week trading range was $1.30 to $3.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.